Name

THP

Alternate names

None

Primary Site

Breast

Histology

None

Radiation

None

Remarks

THP is a chemotherapy regimen used to treat HER2-positive breast cancer.

Drugs for THP

Name

Alternate Names

LIT-976
RP-56976
Taxotere

Abbreviations

None

Category

Chemotherapy

Subcategory

Taxane

NSC Number

628503

Primary Site

Breast
gastric
head & neck
non-small cell lung
ovarian
prostate cancer

Histology

None

Remarks

FDA approved for use on breast, prostate, stomach and NSCLC. Aventis Pharmaceuticals.

Coding

This drug should be coded

Name

Alternate Names

Anti-c-erbB2 monoclonal antibody
Anti-erbB2 monoclonal antibody
Anti-HER2 monoclonal antibody
Anti-HER2/c-erbB2 monoclonal antibody
Anti-p185-HER2 monoclonal antibody
HER2 Mab
HER2 monoclonal antibody
HER2/neu Mab
HER2/neu monoclonal antibody
Herceptin

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Targeted therapy--epidermal growth factor receptor

NSC Number

688097

Primary Site

Breast
colorectal
lung
ovarian
pancreatic
prostate cancer

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Herceptin is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Herceptin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this as chemotherapy.

Phase II (breast, colorectal, lung) Phase III (ovarian, prostate)
Anti HER-2 monoclonal antibody. FDA approved for use on breast cancer. Genentech, NCI.
FDA granted approval 10/2010 for Herceptin in combination with cisplatin and fluropyrimidine (either capecitabine or 5-FU) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarinoma who have not received prior treatment for metastatic disease.

Coding

This drug should be coded

Name

Alternate Names

Omnitarg
Perjeta
R1273

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic agent--tyrosine kinase inhibitor
Humanized monoclonal antibody

NSC Number

900005

Primary Site

Breast

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Pertuzumab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code pertuzumab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.

Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.

Coding

This drug should be coded
Glossary